Core Viewpoint - Enwei Pharmaceutical reported significant growth in its performance for the first half of 2025, driven by the resumption of key products from Henan Xinxin Pharmaceutical and strong online sales, particularly in non-pharmaceutical products [1] Financial Performance - In the first half of 2025, Enwei Pharmaceutical achieved a net profit of 38.34 million yuan, an increase of 113.80% year-on-year [1] - The company's revenue for the same period was 449 million yuan, representing a 15.73% increase compared to the previous year [1] Business Strategy - The company plans to focus on daily operations and production to meet market demand, aiming to launch approximately 20 key products from Henan Xinxin Pharmaceutical by the end of the year [1] - Enwei Pharmaceutical is also looking to expand through mergers and acquisitions, having identified several potential targets since 2024 [1] Product Development - The company aims to develop 8 to 10 product groups with over 100 million yuan in sales within three years starting from 2025 [1] - Current research projects include innovative traditional Chinese medicine and chemical generics, such as nitrofurantoin and elagolix sodium tablets [1] Market Positioning - The acquisition of Henan Xinxin Pharmaceutical is seen as a strategic move to enhance operational efficiency and focus on the traditional Chinese medicine industry chain, which is expected to improve investor recognition and market value [1] Cost Management - The amortization of stock incentive expenses is projected to impact profits by approximately 10 million yuan in 2025 and 3.6 million yuan in 2026 [1]

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 √业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 线上参与公司 年半年度网上业绩说明会的投资者 2025 | | 人员姓名 | | | 时间 | 年 月 日（周三）15:00~16:30 2025 9 3 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | | 1、公司董事长兼首席执行官薛永江 | | 上市公司接待人 | 2、公司副总裁、董事会秘书、财务总监胡大伟 | | 员姓名 | 3、独立董事刘娅 | | | 4、保荐代表人石坡 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、上半年，公司经营业绩实现快速增长，尤其是归母 | | | 净利润增速超过 100%。请问董事长，上半年公司业绩大幅 | | 投资者关系活动 | 增长的主 ...